Evans B D, Raju K S, Calvert A H, Harland S J, Wiltshaw E
Cancer Treat Rep. 1983 Nov;67(11):997-1000.
A phase II study of JM8, an analog of cisplatin, has been carried out in 36 patients with advanced ovarian carcinoma. Thirty-three of these patients had recurrent carcinoma and had been heavily pretreated, either with cytotoxic drugs alone (28 patients) or with cytotoxic drugs and radiotherapy (five patients). All patients had previously received cisplatin, either alone or as part of a combination, and some of them had previously been treated with as many as four different chemotherapy regimens. In addition, three patients with stage III ovarian carcinoma were treated with JM8 as first-line therapy. Twenty-eight of the 33 pretreated patients were evaluable for response, and five partial and two complete remissions were achieved. Of the seven responders, four had previously been shown to be completely resistant to cisplatin, and a fifth had initially responded to, but subsequently relapsed, while receiving cisplatin. Renal, aural, and neurotoxic effects were less than would have been expected with cisplatin, but hematologic toxic effects were common, with a wbc count of less than 2000 X 10(9)/L recorded in six patients, and a platelet count of less than 50,000 X 10(9)/L recorded in eight patients.
对顺铂类似物JM8进行了一项II期研究，入组了36例晚期卵巢癌患者。其中33例患者为复发性癌，且接受过大量预处理，单独使用细胞毒性药物治疗（28例患者）或细胞毒性药物联合放疗（5例患者）。所有患者之前均接受过顺铂治疗，单独使用或作为联合治疗的一部分，其中一些患者之前接受过多达四种不同的化疗方案。此外，3例III期卵巢癌患者接受JM8作为一线治疗。33例预处理患者中有28例可评估疗效，获得了5例部分缓解和2例完全缓解。在7例缓解者中，4例之前被证明对顺铂完全耐药，第5例在接受顺铂治疗时最初有反应，但随后复发。肾脏、听觉和神经毒性作用低于顺铂预期，但血液学毒性作用常见，6例患者白细胞计数低于2000×10⁹/L，8例患者血小板计数低于50000×10⁹/L。
